Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 702836, 11 pages
http://dx.doi.org/10.1155/2010/702836
Review Article

Novel Approaches to Treat Experimental Pulmonary Arterial Hypertension: A Review

Department of Cardiology, Leiden University Medical Center, P. O. Box 9600, 2300 RC Leiden, The Netherlands

Received 11 September 2009; Revised 8 January 2010; Accepted 8 February 2010

Academic Editor: Abdel A. Abdel-Rahman

Copyright © 2010 S. Umar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Sztrymf, A. Yaici, B. Girerd, and M. Humbert, “Genes and pulmonary arterial hypertension,” Respiration, vol. 74, no. 2, pp. 123–132, 2007. View at Publisher · View at Google Scholar · View at PubMed
  2. K. N. Cowan, P. L. Jones, and M. Rabinovitch, “Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis,” Circulation Research, vol. 84, no. 10, pp. 1223–1233, 1999. View at Google Scholar
  3. K. N. Cowan, P. L. Jones, and M. Rabinovitch, “Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease,” Journal of Clinical Investigation, vol. 105, no. 1, pp. 21–34, 2000. View at Google Scholar
  4. K. N. Cowan, A. Heilbut, T. Humpl, C. Lam, S. Ito, and M. Rabinovitch, “Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor,” Nature Medicine, vol. 6, no. 6, pp. 698–702, 2000. View at Publisher · View at Google Scholar · View at PubMed
  5. R. T. Schermuly, E. Dony, H. A. Ghofrani et al., “Reversal of experimental pulmonary hypertension by PDGF inhibition,” Journal of Clinical Investigation, vol. 115, no. 10, pp. 2811–2821, 2005. View at Publisher · View at Google Scholar · View at PubMed
  6. M. E. van Albada, R. M. F. Berger, M. Niggebrugge, R. van Veghel, A. H. Cromme-Dijkhuis, and R. G. Schoemaker, “Prostacyclin therapy increases right ventricular capillarisation in a model for flow-associated pulmonary hypertension,” European Journal of Pharmacology, vol. 549, no. 1–3, pp. 107–116, 2006. View at Publisher · View at Google Scholar · View at PubMed
  7. M. Kataoka, N. Nagaya, T. Satoh et al., “A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 12, pp. 1575–1580, 2005. View at Publisher · View at Google Scholar · View at PubMed
  8. H. Obata, Y. Sakai, S. Ohnishi et al., “Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 2, pp. 195–201, 2008. View at Publisher · View at Google Scholar · View at PubMed
  9. R. T. Schermuly, H. Yilmaz, H. A. Ghofrani et al., “Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 3, pp. 358–363, 2005. View at Publisher · View at Google Scholar · View at PubMed
  10. T. Itoh, N. Nagaya, T. Fujii et al., “A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats,” American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 1, pp. 34–38, 2004. View at Google Scholar
  11. R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani et al., “Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension,” Circulation Research, vol. 94, no. 8, pp. 1101–1108, 2004. View at Publisher · View at Google Scholar · View at PubMed
  12. K. Abe, H. Shimokawa, K. Morikawa et al., “Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats,” Circulation Research, vol. 94, no. 3, pp. 385–393, 2004. View at Publisher · View at Google Scholar · View at PubMed
  13. K. Abe, S. Tawara, K. Oi et al., “Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice,” Journal of Cardiovascular Pharmacology, vol. 48, no. 6, pp. 280–285, 2006. View at Publisher · View at Google Scholar · View at PubMed
  14. B. H. Jiang, S. Tawara, K. Abe, A. Takaki, Y. Fukumoto, and H. Shimokawa, “Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats,” Journal of Cardiovascular Pharmacology, vol. 49, no. 2, pp. 85–89, 2007. View at Publisher · View at Google Scholar · View at PubMed
  15. T. Nagaoka, K. A. Fagan, S. A. Gebb et al., “Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 5, pp. 494–499, 2005. View at Publisher · View at Google Scholar · View at PubMed
  16. S. Tawara, Y. Fukumoto, and H. Shimokawa, “Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats,” Journal of Cardiovascular Pharmacology, vol. 50, no. 2, pp. 195–200, 2007. View at Publisher · View at Google Scholar · View at PubMed
  17. N. S. Hill, R. R. Warburton, L. Pietras, and J. R. Klinger, “Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats,” Journal of Applied Physiology, vol. 83, no. 4, pp. 1209–1215, 1997. View at Google Scholar
  18. M. Nishida, Y. Okada, K. Akiyoshi et al., “Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats,” European Journal of Pharmacology, vol. 496, no. 1, pp. 159–165, 2004. View at Publisher · View at Google Scholar
  19. M. Nishida, K. Eshiro, Y. Okada, M. Takaoka, and Y. Matsumura, “Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension,” Journal of Cardiovascular Pharmacology, vol. 44, no. 2, pp. 187–191, 2004. View at Publisher · View at Google Scholar
  20. M. Ueno, T. Miyauchi, S. Sakai, R. Yamauchi-Kohno, K. Goto, and I. Yamaguchi, “A combination of oral endothelin-A receptor antagonist and oral prostacyclin analogue is superior to each drug alone in ameliorating pulmonary hypertension in rats,” Journal of the American College of Cardiology, vol. 40, no. 1, pp. 175–181, 2002. View at Publisher · View at Google Scholar
  21. C. Guignabert, M. Izikki, L. I. Tu et al., “Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension,” Circulation Research, vol. 98, no. 10, pp. 1323–1330, 2006. View at Publisher · View at Google Scholar · View at PubMed
  22. C. Guignabert, B. Raffestin, R. Benferhat et al., “Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats,” Circulation, vol. 111, no. 21, pp. 2812–2819, 2005. View at Publisher · View at Google Scholar · View at PubMed
  23. X.-Q. Li, Y. Hong, Y. Wang, X.-H. Zhang, and H.-L. Wang, “Sertraline protects against monocrotaline-induced pulmonary hypertension in rats,” Clinical and Experimental Pharmacology and Physiology, vol. 33, no. 11, pp. 1047–1051, 2006. View at Publisher · View at Google Scholar · View at PubMed
  24. M. Miyata, M. Ito, T. Sasajima, H. Ohira, Y. Sato, and R. Kasukawa, “Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist,” Lung, vol. 178, no. 2, pp. 63–73, 2000. View at Google Scholar
  25. E. Hironaka, M. Hongo, A. Sakai et al., “Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats,” Cardiovascular Research, vol. 60, no. 3, pp. 692–699, 2003. View at Publisher · View at Google Scholar
  26. H. Liu, Z.-Y. Liu, and Q. Guan, “Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats,” Interactive Cardiovascular and Thoracic Surgery, vol. 6, no. 5, pp. 608–613, 2007. View at Publisher · View at Google Scholar · View at PubMed
  27. E. Dony, Y.-J. Lai, R. Dumitrascu et al., “Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition,” European Respiratory Journal, vol. 31, no. 3, pp. 599–610, 2008. View at Publisher · View at Google Scholar · View at PubMed
  28. R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani et al., “Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats,” American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 1, pp. 39–45, 2004. View at Google Scholar
  29. S. Pullamsetti, S. Krick, H. Yilmaz et al., “Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration,” Respiratory Research, vol. 6, no. 11, p. 128, 2005. View at Publisher · View at Google Scholar · View at PubMed
  30. M. Clozel, P. Hess, M. Rey, M. Iglarz, C. Binkert, and C. Qiu, “Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats,” Experimental Biology and Medicine, vol. 231, no. 6, pp. 967–973, 2006. View at Google Scholar
  31. J.-F. Jasmin, I. Mercier, J. Dupuis, H. B. Tanowitz, and M. P. Lisanti, “Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy,” Circulation, vol. 114, no. 9, pp. 912–920, 2006. View at Publisher · View at Google Scholar · View at PubMed
  32. N. Homma, Y. Morio, H. Takahashi et al., “Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension,” Respiration, vol. 73, no. 1, pp. 105–112, 2006. View at Publisher · View at Google Scholar · View at PubMed
  33. S. P. Tofovic, E. M. Salah, H. H. Mady, E. K. Jackson, and M. F. Melhem, “Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats,” Journal of Cardiovascular Pharmacology, vol. 46, no. 4, pp. 430–437, 2005. View at Publisher · View at Google Scholar
  34. S. P. Tofovic, X. Zhang, E. K. Jackson, S. Dacic, and G. Petrusevska, “2-methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension,” Vascular Pharmacology, vol. 45, no. 6, pp. 358–367, 2006. View at Publisher · View at Google Scholar · View at PubMed
  35. S. P. Tofovic, X. Zhang, H. Zhu, E. K. Jackson, O. Rafikova, and G. Petrusevska, “2-ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling,” Vascular Pharmacology, vol. 48, no. 4–6, pp. 174–183, 2008. View at Publisher · View at Google Scholar · View at PubMed
  36. T. Nishimura, J. L. Faul, G. J. Berry et al., “Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 10, pp. 1403–1408, 2002. View at Publisher · View at Google Scholar · View at PubMed
  37. P. Guerard, Z. Rakotoniaina, F. Goirand et al., “The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 373, no. 6, pp. 401–414, 2006. View at Publisher · View at Google Scholar · View at PubMed
  38. X. Sun and D. D. Ku, “Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats,” American Journal of Physiology, vol. 294, no. 2, pp. H801–H809, 2008. View at Publisher · View at Google Scholar · View at PubMed
  39. E. Mawatari, M. Hongo, A. Sakai et al., “Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering,” Clinical and Experimental Pharmacology and Physiology, vol. 34, no. 7, pp. 594–600, 2007. View at Publisher · View at Google Scholar · View at PubMed
  40. M. Hongo, E. Mawatari, A. Sakai et al., “Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats,” Journal of Cardiovascular Pharmacology, vol. 46, no. 4, pp. 452–458, 2005. View at Publisher · View at Google Scholar
  41. T. Itoh, N. Nagaya, S. Murakami et al., “C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats,” American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 11, pp. 1204–1211, 2004. View at Publisher · View at Google Scholar · View at PubMed
  42. N. Nagaya, H. Okumura, M. Uematsu et al., “Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats,” American Journal of Physiology, vol. 285, no. 5, pp. H2125–H2131, 2003. View at Google Scholar
  43. H. Zhou, H. Liu, S. L. Porvasnik et al., “Heme oxygenase-1 mediates the protective effects of rapamycin in monocrotaline-induced pulmonary hypertension,” Laboratory Investigation, vol. 86, no. 1, pp. 62–71, 2006. View at Publisher · View at Google Scholar · View at PubMed
  44. H. Maruyama, S. Watanabe, T. Kimura et al., “Granulocyte colony-stimulating factor prevents progression of monocrotaline-induced pulmonary arterial hypertension in rats,” Circulation Journal, vol. 71, no. 1, pp. 138–143, 2007. View at Publisher · View at Google Scholar
  45. H. Sawada, Y. Mitani, J. Maruyama et al., “A nuclear factor-κB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats,” Chest, vol. 132, no. 4, pp. 1265–1274, 2007. View at Publisher · View at Google Scholar · View at PubMed
  46. N. F. Voelkel, R. M. Tuder, J. Bridges, and W. P. Arend, “Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline,” American Journal of Respiratory Cell and Molecular Biology, vol. 11, no. 6, pp. 664–675, 1994. View at Google Scholar
  47. H. Kimura, Y. Kasahara, K. Kurosu et al., “Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1,” Laboratory Investigation, vol. 78, no. 5, pp. 571–581, 1998. View at Google Scholar
  48. J. Lu, H. Shimpo, A. Shimamoto et al., “Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats,” Journal of Thoracic and Cardiovascular Surgery, vol. 128, no. 6, pp. 850–859, 2004. View at Publisher · View at Google Scholar · View at PubMed
  49. H. C. Rosenberg and M. Rabinovitch, “Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension,” American Journal of Physiology, vol. 255, no. 6, pp. H1484–H1491, 1988. View at Google Scholar
  50. J. Maruyama and K. Maruyama, “Impaired nitric oxide-dependent responses and their recovery in hypertensive pulmonary arteries of rats,” American Journal of Physiology, vol. 266, no. 6, pp. H2476–H2488, 1994. View at Google Scholar
  51. Y. Mitani, K. Maruyama, and M. Sakurai, “Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats,” Circulation, vol. 96, no. 2, pp. 689–697, 1997. View at Google Scholar
  52. K. R. Stenmark, M. L. Morganroth, L. K. Remigio et al., “Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension,” American Journal of Physiology, vol. 248, no. 6, pp. H859–H866, 1985. View at Google Scholar
  53. L. Long, A. Crosby, X. Yang et al., “Altered bone morphogenetic protein and transforming growth factor-β signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease,” Circulation, vol. 119, no. 4, pp. 566–576, 2009. View at Publisher · View at Google Scholar · View at PubMed
  54. F. Kamezaki, H. Tasaki, K. Yamashita et al., “Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 2, pp. 219–226, 2008. View at Publisher · View at Google Scholar · View at PubMed
  55. Y. Ikeda, Y. Yonemitsu, C. Kataoka et al., “Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats,” American Journal of Physiology, vol. 283, no. 5, pp. H2021–H2028, 2002. View at Google Scholar
  56. N. Nagaya, C. Yokoyama, S. Kyotani et al., “Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats,” Circulation, vol. 102, no. 16, pp. 2005–2010, 2000. View at Google Scholar
  57. T. Ito, T. Okada, J. Mimuro et al., “Adenoassociated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats,” Hypertension, vol. 50, no. 3, pp. 531–536, 2007. View at Publisher · View at Google Scholar · View at PubMed
  58. Y. D. Zhao, A. I. M. Campbell, M. Robb, D. Ng, and D. J. Stewart, “Protective role of angiopoietin-1 in experimental pulmonary hypertension,” Circulation Research, vol. 92, no. 9, pp. 984–991, 2003. View at Publisher · View at Google Scholar · View at PubMed
  59. T. Ito, T. Okada, H. Miyashita et al., “Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats,” Circulation Research, vol. 101, no. 7, pp. 734–741, 2007. View at Publisher · View at Google Scholar · View at PubMed
  60. S. R. Baber, W. Deng, R. G. Master et al., “Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction,” American Journal of Physiology, vol. 292, no. 2, pp. H1120–H1128, 2007. View at Publisher · View at Google Scholar · View at PubMed
  61. A. I. M. Campbell, M. A. Kuliszewski, and D. J. Stewart, “Cell-based gene transfer to the pulmonary vasculature. Endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension,” American Journal of Respiratory Cell and Molecular Biology, vol. 21, no. 5, pp. 567–575, 1999. View at Google Scholar
  62. A. I. M. Campbell, Y. Zhao, R. Sandhu, and D. J. Stewart, “Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension,” Circulation, vol. 104, no. 18, pp. 2242–2248, 2001. View at Google Scholar
  63. Y. D. Zhao, D. W. Courtman, D. S. Ng et al., “Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer,” American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 2, pp. 182–189, 2006. View at Publisher · View at Google Scholar · View at PubMed
  64. Y. D. Zhao, D. W. Courtman, Y. Deng, L. Kugathasan, Q. Zhang, and D. J. Stewart, “Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease,” Circulation Research, vol. 96, no. 4, pp. 442–450, 2005. View at Publisher · View at Google Scholar · View at PubMed
  65. H. K. Yip, L. T. Chang, C. K. Sun et al., “Autologous transplantation of bone marrow-derived endothelial progenitor cells attenuates monocrotaline-induced pulmonary arterial hypertension in rats,” Critical Care Medicine, vol. 36, no. 3, pp. 873–880, 2008. View at Google Scholar
  66. T. Asahara and A. Kawamoto, “Endothelial progenitor cells for postnatal vasculogenesis,” American Journal of Physiology, vol. 287, no. 3, pp. C572–C579, 2004. View at Publisher · View at Google Scholar · View at PubMed
  67. M. Sahara, M. Sata, T. Morita, K. Nakamura, Y. Hirata, and R. Nagai, “Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation,” Circulation, vol. 115, no. 4, pp. 509–517, 2007. View at Publisher · View at Google Scholar · View at PubMed
  68. W. Raoul, O. Wagner-Ballon, G. Saber et al., “Effects of bone marrow-derived cells on monocrotaline- and hypoxia-induced pulmonary hypertension in mice,” Respiration Research, vol. 8, no. 1, p. 8, 2007. View at Google Scholar
  69. S. Kanki-Horimoto, H. Horimoto, S. Mieno et al., “Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension,” Circulation, vol. 114, supplement 1, pp. I181–I185, 2006. View at Publisher · View at Google Scholar · View at PubMed
  70. M. Takahashi, T. Nakamura, T. Toba, N. Kajiwara, H. Kato, and Y. Shimizu, “Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs,” Tissue Engineering, vol. 10, no. 5-6, pp. 771–779, 2004. View at Publisher · View at Google Scholar · View at PubMed
  71. S. Umar, Y. P. de Visser, P. Steendijk et al., “Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension,” American Journal of Physiology, vol. 297, no. 5, pp. H1606–H1616, 2009. View at Publisher · View at Google Scholar · View at PubMed
  72. X.-X. Wang, F.-R. Zhang, Y.-P. Shang et al., “Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 49, no. 14, pp. 1566–1571, 2007. View at Publisher · View at Google Scholar · View at PubMed